Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Stryker CEO Kevin Lobo to Become Executive Chair; President, COO Spencer Stiles Named Successor

Stryker CEO Kevin Lobo to Become Executive Chair; President, COO Spencer Stiles Named Successor

MT newswireMT newswire2026/10/06 12:56

08:56 AM EDT, 10/06/2026 (MT Newswires) -- Stryker (SYK) Chief Executive Kevin Lobo is stepping down after 14 years and transitioning to the role of executive chair of the board, effective Jan. 1, as part of a planned leadership transition, the company said Tuesday. He will be succeeded by President and Chief Operating Officer Spencer Stiles, who will also be appointed to the board, the company said. Stiles joined the company in 1999, serving in various roles before being named president and chief operating officer in January, the company said. Shares of the company were down 3.7% in recent premarket trading.

08:56 AM EDT, 10/06/2026 (MT Newswires) -- Stryker (SYK) Chief Executive Kevin Lobo is stepping down after 14 years and transitioning to the role of executive chair of the board, effective Jan. 1, as part of a planned leadership transition, the company said Tuesday. He will be succeeded by President and Chief Operating Officer Spencer Stiles, who will also be appointed to the board, the company said. Stiles joined the company in 1999, serving in various roles before being named president and chief operating officer in January, the company said. Shares of the company were down 3.7% in recent premarket trading.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials

Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.

智通财经•2026/10/10 06:21